NCT06818565View on ClinicalTrials.gov

Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.

NANot yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Acute-On-Chronic Liver Failure

Interventions

DRUG

Meropenem Injection

Meropenem 2 gm iv TDS

DRUG

Ceftazidime-avibactam

Ceftazidime-avibactam 2.5 gm iv TDS

DRUG

Teicoplanin

Teicoplanin 400 mg iv BD 3 doses followed by 400mg iv OD

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06818565 - Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. | Biotech Hunter | Biotech Hunter